BioNexus Gene Lab Corp(BGLC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 15 at 4:00 PM ET (Korea 10/16 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.26 | Insider Own | 46.92% | Shs Outstand | 2.4M | Perf Week | -2.27% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.6M | Perf Month | -17.5% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 0.49% | Short Float | 0.65% | Perf Quarter | -26.45% |
| Income | -0.00B | P/S | 1.15 | EPS this Y | - | Inst Trans | 2.28% | Short Ratio | 0.87 | Perf Half Y | -43.93% |
| Sales | 0.00B | P/B | 0.38 | EPS next 5Y | - | ROA | -28.38% | Short Interest | 0.01M | Perf YTD | -69.09% |
| Book/sh | 3.22 | P/C | 1.02 | EPS past 3/5Y | -86.65% - | ROE | -33.66% | 52W High | -79.26% ($5.89) | Perf Year | -76.47% |
| Cash/sh | 1.2 | P/FCF | - | Sales past 3/5Y | -12.09% -8.2% | ROIC | -32.54% | 52W Low | 14.11% ($1.07) | Perf 3Y | -80.69% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 22.76% | Gross Margin | 10.73% | Volatility(W/M) | 7.31% 7.59% | Perf 5Y | -99.15% |
| Dividend TTM | - | EV/Sales | 0.08 | Sales Y/Y TTM | -67.27% | Oper. Margin | -87.18% | ATR (14) | 0.11 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.28 | EPS Q/Q | 65.45% | Profit Margin | -82.36% | RSI (14) | 40.67 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.08 | Sales Q/Q | -96.63% | SMA20 | -8.61% ($1.33) | Beta | 1.94 | Target Price | - |
| Payout | - | Debt/Eq | 0.03 | Earnings | - | SMA50 | -15.77% ($1.45) | Rel Volume | 0.34 | Prev Close | $1.26 |
| Employees | 16 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -43.18% ($2.15) | Avg Volume(3M) | 0.01M | Price | $1.22 |
| IPO | 2020/9/16 | Option/Short | No/Yes | Trades | 12 | Volume | 3,973 | Change | -3.1% |
🧪 BioneXus Gene Lab () is a Southeast Asia-based US Nasdaq-listed company that operates both an industrial chemical raw materials trading business and an RNA-based liquid biopsy (genomic screening) service. It supplies chemical raw materials across Southeast Asia, including Malaysia, Indonesia, and Vietnam, while simultaneously growing its non-invasive diagnostics business, which uses RNA analysis to detect disease biomarkers early.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 34% of its average volume.
BGLC has a sound balance sheet but weak earning power
Of every $100 in sales, $87.18 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $115. Peers typically go for $146.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +73% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.5%.
Tap to view numbers
It ranks #61 of 62 in the industry
Based on market cap of $4M.
BON#58 Bon Natural Life Ltd $9M PER - 
YMAT#59 J-Star Holding Co Ltd $6M PER - 
SNES#60 SenesTech Inc $4M PER - BGLC#61 BioNexus Gene Lab Corp $4M PER - 
CNEY#62 CN Energy Group Inc $3M PER - 
FAQ
What kind of company is BGLC?
BGLC belongs to the Basic Materials sector and operates in the Specialty Chemicals industry.
What is the market cap of BGLC?
The market cap of BGLC is approximately $4M, ranking 5,725 within its sector.
What is the 52-week high and low for BGLC?
BGLC has recorded a 52-week high of $5.89 and a low of $1.07.
